{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+Plan+1%3A+Stratum+1",
    "query": {
      "intervention": "Treatment Plan 1: Stratum 1"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T10:12:28.949Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00920972",
      "title": "Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metabolic Disorders",
        "Hematologic, Immune, or Bone Marrow Disorders",
        "Hemoglobinopathies",
        "Non-malignant Disorders"
      ],
      "interventions": [
        {
          "name": "Treatment Plan 1: Stratum 1",
          "type": "DRUG"
        },
        {
          "name": "Treatment Plan 2: Strata 2, 3, or 4",
          "type": "DRUG"
        },
        {
          "name": "GVHD Regimen A: UCB Recipients",
          "type": "DRUG"
        },
        {
          "name": "GVHD Regimen B: BM Recipients",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "Up to 20 Years"
      },
      "enrollment_count": 220,
      "start_date": "2001-12",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-02T10:12:28.949Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Orange, California • San Diego, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920972"
    },
    {
      "nct_id": "NCT07302776",
      "title": "TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "GVHD",
        "Hematopoietic Cell Transplantation (HCT)",
        "Acute Myeloid Leukemia (AML)",
        "Myelodysplastic Syndromes",
        "Myelofibrosis (MF)",
        "Chronic Myeloid Leukemia (CML)",
        "Chronic Myelomonocytic Leukemia (CMML)"
      ],
      "interventions": [
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Early Tacrolimus Taper Strategy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-07-21",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-02T10:12:28.949Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07302776"
    },
    {
      "nct_id": "NCT02611661",
      "title": "Local Ablative Strategies After Endovascular Radioembolization",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "PET/MRI",
          "type": "DEVICE"
        },
        {
          "name": "Percutaneous ablation",
          "type": "RADIATION"
        },
        {
          "name": "Stereotactic body radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "RADIATION"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2016-01-19",
      "completion_date": "2018-02-13",
      "has_results": false,
      "last_update_posted_date": "2018-08-16",
      "last_synced_at": "2026-10-02T10:12:28.949Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02611661"
    },
    {
      "nct_id": "NCT05407441",
      "title": "Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Atypical Teratoid Rhabdoid Tumor",
        "INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors",
        "SMARCA4-deficient Primary CNS Malignant Tumors",
        "Malignant Rhabdoid Tumor (MRT)",
        "Rhabdoid Tumor of the Kidney (RTK)",
        "Epithelioid Sarcoma",
        "Chordoma"
      ],
      "interventions": [
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Susan Chi, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 49,
      "start_date": "2023-08-10",
      "completion_date": "2029-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-02T10:12:28.949Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05407441"
    },
    {
      "nct_id": "NCT03033992",
      "title": "Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Glioma",
        "Ependymoma",
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)",
          "type": "DEVICE"
        },
        {
          "name": "Concurrent Optune and RT followed by Optune System alone",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 80,
      "start_date": "2017-04-04",
      "completion_date": "2032-07-22",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-10-02T10:12:28.949Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03033992"
    },
    {
      "nct_id": "NCT02644460",
      "title": "Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "Brain Tumor, Recurrent",
        "Solid Tumor, Recurrent",
        "Neuroblastoma, Recurrent, Refractory",
        "Ewing Sarcoma, Recurrent, Refractory",
        "Rhabdomyosarcoma, Recurrent, Refractory",
        "Osteosarcoma, Recurrent, Refractory",
        "Rhabdoid Tumor, Recurrent, Refractory"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 53,
      "start_date": "2016-02",
      "completion_date": "2023-10-10",
      "has_results": false,
      "last_update_posted_date": "2023-10-26",
      "last_synced_at": "2026-10-02T10:12:28.949Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • Atlanta, Georgia",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02644460"
    },
    {
      "nct_id": "NCT03547635",
      "title": "AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Foot Ulcer"
      ],
      "interventions": [
        {
          "name": "AMNIOEXCEL Plus Amniotic Membrane",
          "type": "OTHER"
        },
        {
          "name": "A Marketed Comparator",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Integra LifeSciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2018-05-03",
      "completion_date": "2019-02-26",
      "has_results": true,
      "last_update_posted_date": "2020-07-20",
      "last_synced_at": "2026-10-02T10:12:28.949Z",
      "location_count": 7,
      "location_summary": "Fresno, California • Los Angeles, California • Gainesville, Georgia + 3 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03547635"
    }
  ]
}